Antiviral liquid

Abstract

To provide an antiviral liquid that can be employed as a disinfectant for hand washing or space dispersion, or can serve for food and beverage use.SOLUTION: An antiviral liquid comprises a rush powder and a tea leaf powder in a weight ratio of 2:8 to 8:2, the powders are mixed with a prescribed amount of purified activated water, and the mixed powder of the rush powder and the tea leaf powder is contained at a concentration of 70 μg / mL or higher.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to an antiviral liquid that can be used for hand washing, for spatial spraying, for consumption, etc. [Background technology]

[0002] Influenza is known as a respiratory tract infection caused by the influenza virus. There are four types of influenza viruses: A, B, C, and D, of which types A and B are the pathogenic viruses of seasonal influenza. Seasonal influenza epidemics occur repeatedly around the world, and in Japan, epidemics occur almost every winter. In recent years, infectious diseases caused by new viruses such as the novel coronavirus, SARS, and highly pathogenic influenza have become widespread, becoming a major social problem.

[0003] It has been known that rush grass has antibacterial and antiseptic properties (see, for example, Patent Document 1). Tea leaves are also known to have antibacterial and antiseptic properties. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2013 / 011679 Summary of the Invention [Problem to be solved by the invention]

[0005] The inventors noticed that rushes and tea leaves have antibacterial and antiseptic properties, and after extensive research, discovered that powdering them and mixing them with purified water reduces the infectivity of influenza virus type A (H3N2 strain), leading to the creation of the present invention.An object of the present invention is to provide an antiviral liquid that reduces the infectivity of viruses. [Means for solving the problem]

[0006] An antiviral solution according to one aspect of the present invention is characterized by containing a predetermined amount of rush powder, a predetermined amount of tea leaf powder, and a predetermined amount of purified water.

[0007] In this way, the infectivity of viruses can be reduced by using this antiviral solution as a disinfectant for hand washing, a disinfectant for air spraying, a disinfectant for eating and drinking, etc. Furthermore, this antiviral solution can be used as a suspension as described below, or it can be used as a liquid after leaving the suspension for a predetermined period of time and passing it through a filter to remove precipitates.

[0008] This antiviral liquid is characterized in that it contains the rush powder and the tea leaf powder in a weight ratio within the range of 2:8 to 8:2, and the mixed powder of the rush powder and the tea leaf powder is contained at a concentration of 70 μg / mL or more.

[0009] By doing this, it was found that a certain level of antiviral effect could be achieved by keeping the weight ratio of rush powder to tea leaf powder within the above range and mixing this with purified water to a concentration of 70 μg / mL or more.

[0010] It was found that the antiviral effect was reduced when the weight ratio of rush powder to tea leaf powder was within the above range, but when the weight ratio of rush powder to tea leaf powder was outside the above range, for example, when the rush powder was less than 2 / 10. Similarly, the antiviral effect was also reduced when the concentration of these powders was less than 70 μg / mL, and no antiviral effect was obtained at a concentration of 62.5 μg / mL.

[0011] This antiviral solution is characterized in that the weight of the rush powder is equal to or greater than the weight of the tea leaf powder.

[0012] It was found that by doing this, the antiviral effect was enhanced by making the weight of the rush powder equal to or greater than the weight of the tea leaf powder.

[0013] This antiviral solution is characterized in that the weight ratio of the rush powder to the tea leaf powder is within the range of 7:3 to 9:1.

[0014] It was found that by setting the weight ratio of rush powder to tea leaf powder within the above range, the antiviral effect was further enhanced.

[0015] This antiviral liquid is characterized by containing a powder obtained by mixing the rush powder and the tea leaf powder at a concentration of 70 μg / mL or more.

[0016] It was found that by doing this, the antiviral effect was further enhanced when the powder obtained by mixing rush powder and the tea leaf powder was contained at a concentration of 70 μg / mL or more.

[0017] This antiviral solution is characterized in that the rush powder is powder of an original species of rush grown in Japan.

[0018] In this way, it was found that using powder of the original Japanese rush species, which has been growing since ancient times, instead of rush powder, a high antiviral effect was achieved.In addition to the original Japanese rush species, there are also foreign rush species and relatively new varieties of rush, and when comparative tests were conducted using various types of rush, it was found that a high antiviral effect was obtained when powder of the original rush species was used.

[0019] This antiviral solution is characterized in that the rush powder and the tea leaf powder are powders of 30 μm or less.

[0020] This antiviral liquid is characterized in that it is a suspension containing the rush powder, the tea leaf powder, and the purified water.

[0021] One method for producing an antiviral solution is to mix rush and tea leaf powder with water and distill the mixture to extract the components, but it has been found that distillation produces a lower antiviral effect. Also, a suspension produces a higher antiviral effect than extractions made by other methods.

[0022] It has been found that this increases the effectiveness of the antiviral solution. It is preferable that the powder be 10 μm or less in size.

[0023] This antiviral solution is characterized by being sterilized or disinfected.

[0024] In this way, bacteria that may have inadvertently adhered to the rush powder and tea leaf powder, or bacteria that may have inadvertently mixed in the air when the rush powder, tea leaf powder, and purified water are mixed, can be removed by sterilizing and sterilizing. The sterilizing and sterilizing processes can be carried out, for example, using an autoclave that uses high-temperature, high-pressure steam.

[0025] The disinfectant according to one aspect of the present invention is characterized by using a suspension, which can be used, for example, as a disinfectant for hand washing.

[0026] One aspect of the present invention is a spatial spraying device that sprays into space, and is equipped with a tank that stores liquid and a spray unit that turns the liquid into a mist and sprays it into the space, and ceramics are arranged in the tank.The tank is filled with a predetermined amount of tap water, a predetermined amount of rush powder, and a predetermined amount of tea leaf powder, and the suspension is turned into a mist and sprayed into the space.

[0027] In this way, by placing a predetermined amount of rush powder and a predetermined amount of tea leaf powder in a tank equipped with ceramics and then adding tap water, the tap water is cleaned and activated by the ceramics, becoming purified water, which becomes a suspension of rush powder, tea leaf powder, and purified water.By dispersing this in a mist into the air, it is possible to spray a mist of antiviral liquid with antiviral effects into the air.

[0028] A method for producing an antiviral liquid according to one aspect of the present invention comprises the steps of: step A: crushing rushes into powder; step B: crushing tea leaves into powder; and step C: mixing a predetermined amount of the rush powder and a predetermined amount of the tea leaf powder with a predetermined amount of purified water. In this way, an antiviral liquid with antiviral effects can be easily produced.

[0029] This method for producing an antiviral solution is characterized by further comprising, prior to step C, step D of pouring tap water into a container containing ceramics to produce purified water.

[0030] The method for producing this antiviral liquid is characterized in that in step C, the rush powder and the tea leaf powder are blended in a weight ratio within the range of 2:8 to 8:2, and mixed with the purified water, so that the concentration of the mixed rush powder and tea leaf powder is adjusted to 70 μg / mL or more.

[0031] The method for producing this antiviral liquid is characterized in that in step C, the rush powder is blended so that its weight is equal to or greater than the weight of the tea leaf powder, and mixed with the purified water, and the concentration of the mixture of the rush powder and the tea leaf powder is adjusted to 70 μg / mL or more.

[0032] This method for producing an antiviral liquid is characterized in that in step C, the rush powder and the tea leaf powder are blended in a weight ratio within the range of 7:3 to 9:1, and mixed with the purified water, so that the concentration of the mixed rush powder and tea leaf powder is adjusted to 70 μg / mL or more.

[0033] The method for producing this antiviral liquid is characterized in that the rush powder and tea leaf powder are mixed with the purified water to adjust the concentration of the mixed powder to 100 μg / mL or more.

[0034] This method for producing an antiviral liquid is characterized in that in steps A and B, the rush and tea leaves are powdered to a size of 30 μm or less.

[0035] This method for producing an antiviral liquid is characterized in that the step C is a step of mixing the rush powder, the tea leaf powder, and the purified water to form a suspension.

[0036] This method for producing an antiviral solution is characterized in that the rush used is an original species of rush grown in Japan.

[0037] This method for producing an antiviral solution is characterized by further comprising, after step C, step E of sterilizing the solution with high-temperature, high-pressure steam. [Effects of the Invention]

[0038] The antiviral solution of the present invention can reduce the infectivity of viruses. Therefore, it can be used as a disinfectant for hand washing, for airborne spraying, for consumption, etc. Furthermore, since the rush powder, tea leaf powder, and purified water are not harmful substances or chemicals, they are not irritating or toxic and can be used safely for disinfection, etc. [Brief explanation of the drawings]

[0039] [Figure 1] FIG. 1 is an explanatory diagram of a method for preparing an evaluation sample. [Figure 2] FIG. 10 is a diagram showing test results. [Figure 3] This is an image of virus infection in a 96-well plate. [Figure 4] (a) and (b) are diagrams showing non-infected and infected cells with influenza virus, respectively. DETAILED DESCRIPTION OF THE INVENTION

[0040] <1. Antiviral solution> An antiviral solution according to one embodiment of the present invention will be described below, but the present invention is not limited to this embodiment. In this embodiment, the antiviral solution may be referred to as antiviral water, and the purified water may be referred to as Moebius water.

[0041] One example of the antiviral water according to this embodiment is a suspension prepared by mixing a predetermined amount of rush powder and a predetermined amount of tea leaf powder and then mixing the mixture with a predetermined amount of purified water. More specifically, the suspension is prepared by mixing rush powder and tea leaf powder in a weight ratio of 2:8 to 8:2 and adjusting the purified water to a final concentration of 100 μg / mL or more. The antiviral water of the present invention can be used as a suspension or can be filtered to remove precipitates.

[0042] The rush used here is a native species of rush that has been growing in Japan since ancient times. The purified water is tap water that has been brought into contact with ceramics or passed through a water purifier to remove impurities such as chlorine, heavy metals, and radioactive materials. However, using tap water or natural water as is has a low antiviral effect.

[0043] Furthermore, by keeping the weight ratio of rush powder to tea leaf powder within the above range and mixing this with purified water to a concentration of 70 μg / mL or more, an antiviral effect can be obtained. Furthermore, when the concentration of these powders is 100 μg / mL or more, a higher antiviral effect can be obtained. Furthermore, when the powder concentration is less than 62.5 μg / mL, no antiviral effect can be obtained.

[0044] Furthermore, in terms of the antiviral effect of the antiviral liquid, the weight ratio of rush powder to tea leaf powder is preferably equal to or greater than the tea leaf powder, and more preferably is 7:3 to 9:1.

[0045] In addition, in terms of the antiviral effect of the antiviral liquid, the rush powder and tea leaf powder are preferably powders of 30 μm or less, and more preferably powders of 10 μm or less.

[0046] Furthermore, in order to achieve the antiviral effect of the antiviral liquid, it is preferable to mix the rush powder, tea leaf powder, and purified water, and then use an autoclave or similar device to sterilize any bacteria attached to the rushes or tea leaves or in the air.

[0047] Furthermore, by using the above antiviral liquid as a disinfectant for hand washing, a disinfectant for air spraying, or for eating and drinking, the infectivity of viruses such as influenza viruses and coronaviruses can be reduced.

[0048] Furthermore, since the rush powder, tea leaf powder, and purified water are not harmful substances, they are safe to spray or come into contact with, can be used for disinfection, and are not irritating or toxic.

[0049] <2. Method of manufacturing antiviral solution> This antiviral solution is produced as follows. (1) Dried rush is crushed using a crusher or the like until it becomes a powder of, for example, 10 μm or less.

[0050] (2) Dried tea leaves are crushed in a grinder or other device until they are powdered to a size of 10 μm or less. Even if dried stems are mixed in with the tea leaves, a certain level of effectiveness can be achieved.

[0051] (3) Tap water is passed through a ceramic water purifier to obtain purified water. The order of steps (1) to (3) can be reversed as long as the rush powder, tea leaf powder, and purified water are obtained.

[0052] (4) Next, mix the rush powder and tea leaf powder, add it to purified water, and mix to make a suspension. Adjust the concentration of rush powder and tea leaf powder to 1 mg / mL. Note that 1 mg / mL is an example; a concentration of 100 μg / mL or more will provide sufficient antiviral effect.

[0053] (5) The suspension is then autoclaved to sterilize it.

[0054] (6) The suspension removed from the autoclave is used as the antiviral solution.

[0055] <3. How to use the antiviral solution> (1) Disinfectant The antiviral solution produced as described above can be used as follows. For example, the antiviral solution can be placed in a disinfectant tank of a push-type pump for hand washing, and the antiviral solution can be sprayed by pushing it. In this case, the antiviral solution can be a suspension, or a filtered solution from which precipitates have been removed can be used.

[0056] In addition to being used for hand washing, it can also be used as a disinfectant to spray on cups, tables, and other objects.

[0057] This antiviral liquid can be made from rush powder, tea leaf powder, and purified water, and is non-toxic and safe to use because it does not contain any harmful substances or chemicals. It also does not contain any highly irritating substances such as alcohol, making it ideal for hand washing as it is less likely to cause rough hands.

[0058] (2) Sprayer (spatial dispersion device) This antiviral liquid can also be used by putting it in a sprayer that sprays the antiviral liquid in the form of a mist into space.

[0059] In this case, a sprayer equipped with a tank for storing the liquid and a spray unit for spraying the liquid into a mist into the air is used. The tank is fitted with ceramic balls, and approximately 5 μm rush powder and approximately 5 μm tea leaf powder are placed in the tank in a weight ratio of, for example, 8:2. Tap water is then added and mixed so that the total weight of the rush powder and tea leaf powder is 1 mg / mL, creating an antiviral suspension.

[0060] The spray unit then sucks up the suspension from the tank and sprays the antiviral liquid into the air.The tank contains tap water, which is purified and activated by the action of the ceramic balls (which adsorb and remove heavy metals in the water (lead, cadmium, aluminum, etc.), have antibacterial and bacterial growth effects).

[0061] <4. Antiviral Solution Effect Test> Next, a viral infectivity evaluation test will be described. The inventors conducted the following evaluation test to evaluate the antiviral effect of the antiviral solution of the present embodiment described above.

[0062] As shown in Figure 1, rush powder 1 and tea leaf powder 2 were mixed in a weight ratio of 8:2 and adjusted to a concentration of 1 mg / mL with purified water.The mixture was then placed in an autoclave 3 and sterilized with high-temperature, high-pressure steam.

[0063] The suspension after autoclaving was designated as evaluation sample 4, and evaluation sample 4 and virus 5 were mixed at a weight ratio of 1:9. After leaving the mixture for a predetermined time (for example, 2 hours in this embodiment), the precipitate was removed through filter 6, and the mixture was allowed to infect host cells 7, and the infectivity titer was evaluated.

[0064] In other words, the evaluation sample and virus fluid (influenza virus type A (H3N2)) are mixed, and the virus fluid is collected after two hours.The virus fluid collected after two hours is then allowed to act on host cells, and the infectivity of the virus is evaluated (see Figure 2).

[0065] The specific test conditions are as follows: (Evaluation sample) A suspension was prepared by mixing rush powder 1 and tea leaf powder 2 in a weight ratio of 8:2 and adding it to purified water (final concentration after mixing with virus solution: 100 μg / mL).

[0066] (Virus used) Influenza virus type A (H3N2) A / Aichi / 2 / 68, VR-1680 strain

[0067] (host cell) Canine renal tubular epithelial (Madin-Darby canine kidney: MDCK) cells

[0068] (Culture medium used) Cell growth medium: Minimum Essential Medium (MEM) (containing 1% penicillin-streptomycin, 10% fetal bovine serum (FBS) and non-essential amino acids) Cell maintenance medium: Minimum Essential Medium (MEM) (containing 1% penicillin-streptomycin)

[0069] (Host cell culture) Madin-Darby canine kidney (MDCK) cells, which serve as the host for influenza virus, were cultured in a 10-cm dish using a growth medium until they reached 90% confluence.

[0070] (Preparation of virus solution) The growth medium was removed from MDCK cells cultured until they were 90% confluent, and 1 mL of influenza virus type A (H3N2) purchased from ATCC was inoculated and incubated in a CO2 incubator (35°C, 5% CO2) for 1 hour.

[0071] After 1 hour, 9 mL of maintenance medium was added, and the cells were cultured in a CO2 incubator (35°C, 5% CO2) for 4 days. After the culture, cell morphological changes were observed under an optical microscope to confirm that morphological changes due to virus infection had occurred. Next, the culture supernatant was centrifuged (1000 x g, 10 minutes), and the resulting supernatant was used as the virus solution in the test.

[0072] (Virus infectivity evaluation test) 0.1 mL of the virus solution prepared using the method above was allowed to react with 0.9 mL of the evaluation sample for 2 hours at room temperature. After centrifugation, the supernatant was passed through a 0.2 μm filter to remove the evaluation sample. The filtered virus solution was diluted 2-fold with maintenance medium to prepare the working solution. The working solution was further diluted 10-fold with maintenance medium to create a dilution series.

[0073] MDCK cells were pre-cultured in a 10 cm dish using growth medium until they became confluent. After that, they were washed with phosphate-buffered saline (PBS), resuspended in medium, and then plated at 1.0 × 10 cells per well in a 96-well plate. 4 The cells were seeded at a density of 1000 cells / well and cultured overnight in a CO2 incubator (37°C, 5% CO2) (see Figure 3).

[0074] The growth medium was removed from the cultured MDCK cells, and 100 μL of the diluted solution was added to each of the eight wells in each dilution row. For comparison, only the maintenance medium was added to the last row. The virus-infected cells were cultured for three days in a CO2 incubator (35°C, 5% CO2). After the culture, cell degeneration due to virus infection was confirmed under an inverted microscope, and the cells were stained with crystal violet. The virus infectivity titer (TCID 50 ) was calculated using the Kerber formula.

[0075] (Test results) A mixture of purified water containing rush powder and tea leaf powder in a ratio of 8:2 was allowed to react with influenza virus type A (H3N2) for two hours. After two hours, the mixture was infected into MDCK cells, which are host cells for the influenza virus, and the infectivity of the virus was evaluated.

[0076] As a result, as shown in Figure 2 and Table 1, the influenza virus that was exposed to purified water mixed with rush powder and tea leaf powder in a ratio of 8:2 for 2 hours showed a TCID 50 has decreased by more than three digits.

[0077] This indicates that a mixture of rush powder and tea leaf powder in a ratio of 8:2 mixed with purified water (final concentration 100 μg / mL) is effective in reducing the infectivity of influenza virus type A (H3N2) by more than 99.9%. Figure 4(a) and (b) show non-infected and infected cells, respectively.

[0078] [Table 1]

[0079] From the above results, it was found that mixing rush powder and tea leaf powder in an 8:2 ratio and adjusting the final concentration to 100 μg / mL or more with purified water has a very high antiviral effect.

[0080] The antiviral water of the above-mentioned examples has been confirmed to be highly effective against influenza viruses such as influenza A virus, but it is expected to also be effective against coronaviruses (e.g., human coronavirus 229E), which are enveloped single-stranded positive-strand RNA viruses similar to influenza viruses.

[0081] Furthermore, while the above examples illustrate the results of efficacy tests when the weight ratio of rush powder to tea leaf powder was 8:2, a certain level of antiviral effect can be obtained by mixing rush powder and tea leaf powder at a weight ratio of 2:8 to 8:2. The antiviral effect is enhanced by making the weight of rush powder equal to or greater than the weight of tea leaf powder, and is further enhanced by making the weight ratio of rush powder to tea leaf powder 7:3 to 9:1. Similarly, a certain level of antiviral effect can be obtained when the concentration of the rush and tea leaf powder mixture in the antiviral solution is 70 μg / mL or higher, and the antiviral effect is enhanced at a concentration of 100 μg / mL or higher. Note that no antiviral effect was obtained at a concentration of 62.5 μg / mL. [Explanation of symbols]

[0082] 1. Igusa powder 2. Tea leaf powder 3. Autoclave 4 Evaluation sample 5. Viruses 6 Filters 7 Host cells

Claims

1. A predetermined amount of rush powder; a predetermined amount of tea leaf powder; A predetermined amount of purified water; characterized in that it comprises Antiviral fluid.

2. the rush powder and the tea leaf powder are contained in a weight ratio within a range of 2:8 to 8:2, The powder obtained by mixing the rush powder and the tea leaf powder has a concentration of 70 μg / mL or more. The antiviral solution according to claim 1.

3. The weight of the rush powder is equal to or greater than the weight of the tea leaf powder. The antiviral solution according to claim 2.

4. The weight ratio of the rush powder to the tea leaf powder is within the range of 7:3 to 9:

1. The antiviral solution according to claim 3.

5. The powder obtained by mixing the rush powder and the tea leaf powder has a concentration of 100 μg / mL or more. The antiviral solution according to any one of claims 2 to 4.

6. The rush powder is a powder of an original rush species produced in Japan. The antiviral solution according to claim 1.

7. The rush powder and the tea leaf powder are powders of 30 μm or less. The antiviral solution according to claim 1.

8. The suspension is characterized by comprising the rush powder, the tea leaf powder, and the purified water. The antiviral solution according to claim 7.

9. characterized in that it is sterilized or sterile, The antiviral solution according to claim 1.

10. The suspension according to claim 8 is used. Disinfectant.

11. It is a space spraying device that sprays into the space, a tank containing a liquid; a spray unit that sprays the liquid into a mist into a space, Ceramics are disposed in the tank, The tank is charged with a predetermined amount of tap water, a predetermined amount of rush powder, and a predetermined amount of tea leaf powder, and the suspension is atomized and sprayed into the space. Spatial dispersion device.

12. A method for producing an antiviral solution, A process A of crushing the rush into powder; A step B of grinding the tea leaves into powder; A step C of mixing a predetermined amount of the rush powder and a predetermined amount of the tea leaf powder with a predetermined amount of purified water; characterized in that it comprises Method for producing antiviral solution.

13. Prior to the step C, a step D is further provided in which tap water is poured into a container containing the ceramics to obtain purified water. The method for producing the antiviral solution according to claim 12.

14. The step C is characterized in that the rush powder and the tea leaf powder are blended in a weight ratio within a range of 2:8 to 8:2, and mixed with the purified water to adjust the concentration of the mixed powder of the rush powder and the tea leaf powder to 70 μg / mL or more. The method for producing the antiviral solution according to claim 12.

15. The step C is characterized in that the rush powder is blended so that the weight of the rush powder is equal to or greater than the weight of the tea leaf powder, and mixed with the purified water to adjust the concentration of the mixed rush powder and tea leaf powder to 70 μg / mL or more. The method for producing the antiviral solution according to claim 12.

16. The step C is characterized in that the rush powder and the tea leaf powder are blended in a weight ratio within a range of 7:3 to 9:1, and mixed with the purified water to adjust the concentration of the mixed powder of the rush powder and the tea leaf powder to 70 μg / mL or more. The method for producing the antiviral solution according to claim 12.

17. The powder is mixed with the purified water to adjust the concentration of the mixed powder of the rush and the tea leaf powder to 100 μg / mL or more. A method for producing the antiviral solution according to any one of claims 14 to 16.

18. In the steps A and B, the rush and the tea leaves are powdered to a size of 30 μm or less. The method for producing the antiviral solution according to claim 12.

19. The step C is a step of mixing the rush powder, the tea leaf powder, and the purified water to form a suspension. The method for producing the antiviral solution according to claim 12.

20. The rush is a Japanese original rush. The method for producing the antiviral solution according to claim 12.

21. The method further comprises a step E of sterilizing the product using high-temperature and high-pressure steam after the step C. The method for producing the antiviral solution according to claim 13.

Images